<DOC>
	<DOCNO>NCT02686008</DOCNO>
	<brief_summary>This open label pilot study evaluate pharmacodynamics safety single agent olaparib administer 300mg bid ( twice day ) 14 day orally patient human papillomavirus ( HPV ) -positive human papillomavirus ( HPV ) -negative head neck squamous cell carcinoma ( HNSCC )</brief_summary>
	<brief_title>Pharmacodynamic Study Assess Anti-proliferative Activity PARP Inhibitor Olaparib Patients With HPV Positive HPV Negative HNSCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Histologically confirm HNSCC surgically resectable disease No prior chemotherapy radiation therapy treatment observe HNSCC Patients must provide write informed consent Age &gt; =18 year age Eastern Cooperative Oncology Group ( ECOG ) Performance Status score &lt; 2 Normal organ bone marrow function measure within 28 day prior administration study treatment define : Hemoglobin &gt; = 10 g/dL blood transfusion 28 day prior entry/randomization Absolute neutrophil count &gt; =1.5 x 10^9/L No feature suggest MDS/AML peripheral blood smear White blood cell &gt; 3 x 10^9/L Platelet count &gt; = 100 x 10^9/L Total bilirubin &lt; = 1.5 x institutional upper limit normal ( ULN ) AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 x institutional upper limit normal unless liver metastasis present case must &lt; 5x ULN Serum creatinine &lt; = 1.5 x institutional ULN OR creatinine clearance &gt; = 50 mL/min/1.73 m^2 patient creatinine level institutional normal Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation must negative serum urine pregnancy test within 1 week prior begin treatment trial Must abler understand sign write informed consent document Patients know brain metastasis . Patients may receive WBRT within 14 day focal radiation within 1 week cycle 1 , day 1 . The patient receive stable dose corticosteroid study long start least 28 day prior treatment Women must pregnant breastfeeding Patients know hypersensitivity olaparib excipients product Patients receive investigational agent within 4 week start study Involvement planning and/or conduct study Any previous treatment PARP inhibitor , include olaparib Concomitant use know CYP3A4 inhibitor ketoconazole , itraconazole , ritonavir , indinavir , saquinavir , telithromycin , clarithromycin , nelfinavir Persistent toxicity ( &gt; =CTCAE grade 2 ) Resting ECG QTC &gt; 470msec 2 time point within 24 hour period family history long QT syndrome Blood transfusion within 1 month prior study start Patients myelodysplastic syndrome/acute myeloid leukemia Major surgery within 14 day start study treatment patient must recover effect major surgery Patients consider poor medical risk due serious , uncontrolled medical disorder , nonmalignant systemic disease active , uncontrolled infection . Unable swallow oral medication Immunocompromised patient , e.g. , patient know serologically positive HIV receive antiviral therapy Known active hepatic disease Uncontrolled seizure Previous cancer , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumor curatively treat evidence disease 5 year Currently warfarin ( subcutaneous heparin permit )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>